VG 3927
Alternative Names: VG-3927Latest Information Update: 26 Sep 2024
Price :
$50 *
At a glance
- Originator Vigil Neuroscience
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action TREM2 protein-stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 28 Jul 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 06 Oct 2023 Phase-I clinical trials in Alzheimer's disease (In volunteers) (PO) (Vigil Neurosciences pipeline, October 2023) (NCT06343636)
- 06 Oct 2023 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Alzheimer's disease released by Vigil Neurosciences